2013
Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO
Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Özduman K, Avşar T, Li J, Murray PB, Henegariu O, Yilmaz S, Günel JM, Carrión-Grant G, Yılmaz B, Grady C, Tanrıkulu B, Bakırcıoğlu M, Kaymakçalan H, Caglayan AO, Sencar L, Ceyhun E, Atik AF, Bayri Y, Bai H, Kolb LE, Hebert RM, Omay SB, Mishra-Gorur K, Choi M, Overton JD, Holland EC, Mane S, State MW, Bilgüvar K, Baehring JM, Gutin PH, Piepmeier JM, Vortmeyer A, Brennan CW, Pamir MN, Kılıç T, Lifton RP, Noonan JP, Yasuno K, Günel M. Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013, 339: 1077-1080. PMID: 23348505, PMCID: PMC4808587, DOI: 10.1126/science.1233009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrain NeoplasmsChromosomes, Human, Pair 22DNA Mutational AnalysisFemaleGenes, Neurofibromatosis 2Genomic InstabilityGenomicsHumansKruppel-Like Factor 4Kruppel-Like Transcription FactorsMaleMeningeal NeoplasmsMeningiomaMiddle AgedMutationNeoplasm GradingProto-Oncogene Proteins c-aktReceptors, G-Protein-CoupledSmoothened ReceptorTumor Necrosis Factor Receptor-Associated Peptides and Proteins
2012
Neurosurgical Approach
Moliterno JA, Patel TR, Piepmeier JM. Neurosurgical Approach. The Cancer Journal 2012, 18: 20-25. PMID: 22290253, DOI: 10.1097/ppo.0b013e3183243f6e3.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBrain NeoplasmsCombined Modality TherapyGlioblastomaHumansMiddle AgedConceptsMagnetic resonance imagingTumor cellsResonance imagingAggressive surgical resectionAggressive tumor removalFunctional brain tissueFrequency of seizuresExtent of resectionGoal of surgeryInfiltrative tumor cellsPreferred initial stepFunctional magnetic resonance imagingProliferative tumor cellsAdjuvant therapyAggressive resectionSurgical resectionTumors recurCritical cortical regionsNeurologic impairmentTumor burdenProspective studyTumor resectionTumor removalInfiltrative tumorsMalignant gliomas
2010
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma†
Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, Shaffrey M, Ram Z, Piepmeier J, Prados M, Croteau D, Pedain C, Leland P, Husain SR, Joshi BH, Puri RK, Group F. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma†. Neuro-Oncology 2010, 12: 871-881. PMID: 20511192, PMCID: PMC2940677, DOI: 10.1093/neuonc/nop054.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic AgentsBrain NeoplasmsCarmustineCatheters, IndwellingConvectionDecanoic AcidsDrug Administration RoutesExotoxinsFemaleGlioblastomaHumansInterleukin-13Kaplan-Meier EstimateMagnetic Resonance ImagingMaleMiddle AgedNeoplasm Recurrence, LocalPolyestersRecombinant Fusion ProteinsYoung AdultConceptsConvection-enhanced deliveryCintredekin besudotoxGliadel wafersMedian survivalTumor resectionGlioblastoma multiformeEfficacy-evaluable populationAdverse event profileHealth-related qualityPhase III evaluationTime of randomizationEvaluable populationTertiary endpointsPrimary endpointAdult patientsBaseline characteristicsFirst recurrenceOverall survivalPulmonary embolismActive comparatorTreatment armsIL13-PE38QQRIntraparenchymal catheterSurvival differencesGBM patients
2007
Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study Group
Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK. Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study Group. Journal Of Clinical Oncology 2007, 25: 837-844. PMID: 17327604, DOI: 10.1200/jco.2006.08.1117.Peer-Reviewed Original ResearchConceptsConvection-enhanced deliveryIntracerebral convection-enhanced deliveryCintredekin besudotoxRecurrent malignant gliomaMalignant gliomasGlioblastoma multiformeMedian survivalCatheter placementTumor resectionInfusion durationProcedure-related adverse eventsFavorable risk-benefit profilePhase I clinical studyBetter drug distributionDirect intracerebral deliveryOptimal drug distributionOverall median survivalPortion of patientsRisk-benefit profileDevastating brain tumorDrug distributionAdverse eventsHigh tissue concentrationsIntracerebral deliveryTumor necrosis
2006
The Interactions of Polarographic Measurements of Oxygen Tension and Histological Grade in Human Glioma
Lally BE, Rockwell S, Fischer DB, Collingridge DR, Piepmeier JM, Knisely JP. The Interactions of Polarographic Measurements of Oxygen Tension and Histological Grade in Human Glioma. The Cancer Journal 2006, 12: 461-466. PMID: 17207315, DOI: 10.1097/00130404-200611000-00005.Peer-Reviewed Original ResearchConceptsHistological gradeHigh-grade gliomasLow-grade gliomasTumor oxygen tensionUnivariate analysisOxygen tensionGrade gliomasSignificant independent prognostic indicatorExtent of surgeryType of anesthesiaIndependent prognostic indicatorEppendorf pO2 histographTissue oxygen tensionNormal brain tissueImplications of hypoxiaOverall survivalProspective trialPatient ageEntire cohortPrognostic indicatorPatient genderPoor survivalMedian pO2PatientsPO2 histographDiffusion MRI in the early diagnosis of malignant glioma
Baehring JM, Bi WL, Bannykh S, Piepmeier JM, Fulbright RK. Diffusion MRI in the early diagnosis of malignant glioma. Journal Of Neuro-Oncology 2006, 82: 221-225. PMID: 17029014, DOI: 10.1007/s11060-006-9273-3.Peer-Reviewed Original ResearchMeSH KeywordsAgedBrain NeoplasmsDiffusion Magnetic Resonance ImagingEarly DiagnosisFemaleGliomaHumansMaleMiddle AgedConceptsDiffusion-weighted imagingMalignant gliomasApparent diffusion coefficient (ADC) mapsCentral necrosisNodular enhancing lesionsResultsOf 89 patientsTimely definitive diagnosisSubset of patientsClinical decision-making processBrain Tumor CenterFurther tumor growthHigh-grade gliomasTypical radiographic presentationTime of imagingSubset of casesLow signal intensityDiffusion coefficient mapsConclusionsThe diagnosisDefinitive diagnosisEloquent areasEnhancing lesionsMass lesionRadiographic presentationRim enhancementInclusion criteria
2005
Novel Tumor-Specific Isoforms of BEHAB/Brevican Identified in Human Malignant Gliomas
Viapiano MS, Bi WL, Piepmeier J, Hockfield S, Matthews RT. Novel Tumor-Specific Isoforms of BEHAB/Brevican Identified in Human Malignant Gliomas. Cancer Research 2005, 65: 6726-6733. PMID: 16061654, DOI: 10.1158/0008-5472.can-05-0585.Peer-Reviewed Original ResearchConceptsBEHAB/brevicanHigh-grade gliomasMalignant gliomasBrain tumorsNew potential therapeutic targetsPrimary brain tumorsNormal adult brainDeadly brain tumorCentral nervous systemPotential therapeutic targetLow-grade gliomasHuman malignant gliomasNew therapeutic strategiesPathologic courseSimilar histologyBenign gliomasAdult brainTherapeutic strategiesDiffuse invasionTherapeutic targetGlioma progressionNervous systemInvasive abilityBrain tissueGliomas
2001
Patterns of functional magnetic resonance imaging activation in association with structural lesions in the rolandic region: a classification system.
Carpentier A, Constable R, Schlosser M, de Lotbinière A, Piepmeier J, Spencer D, Awad I. Patterns of functional magnetic resonance imaging activation in association with structural lesions in the rolandic region: a classification system. Journal Of Neurosurgery 2001, 94: 946-54. PMID: 11409524, DOI: 10.3171/jns.2001.94.6.0946.Peer-Reviewed Original ResearchConceptsFMR imaging activationSurgical interventionRolandic regionMotor cortex plasticityMotor task paradigmFunctional magnetic resonance imagingMotor skillsMagnetic resonance imagingSevere motor impairmentFunctional magnetic resonanceFunctional recoveryLesion sideCortical abnormalitiesMotor cortexControl volunteersCortical malformationsStructural lesionsContralateral hemisphereArteriovenous malformationsBrain lesionsSurgical proceduresMotor impairmentPathological lesionsFunctional reorganizationAuthors' institution
1999
Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue
Collingridge D, Piepmeier J, Rockwell S, Knisely J. Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiotherapy And Oncology 1999, 53: 127-131. PMID: 10665789, DOI: 10.1016/s0167-8140(99)00121-8.Peer-Reviewed Original Research
1997
Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study.
Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL, Piepmeier J, Sonntag VK, Wagner F, Wilberger JE, Winn HR, Young W. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997, 277: 1597-604. PMID: 9168289, DOI: 10.1001/jama.277.20.1597.Peer-Reviewed Original ResearchConceptsAcute spinal cord injurySpinal cord injuryNational Acute Spinal Cord Injury StudyFunctional Independence MeasureHours of injuryCord injuryTirilazad groupRegimen groupMethylprednisolone infusionAcute Spinal Cord Injury StudySpinal Cord Injury StudySpinal cord injury centerEfficacy of methylprednisoloneImproved motor recoveryMotor recovery rateAdministration of methylprednisoloneMotor function changesSteroid therapyMethylprednisolone groupSevere sepsisTirilazad mesylateMotor recoveryControlled TrialsInitial presentationIntravenous bolus
1996
BEHAB (brain enriched hyaluronan binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines.
Jaworski D, Kelly G, Piepmeier J, Hockfield S. BEHAB (brain enriched hyaluronan binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines. Cancer Research 1996, 56: 2293-8. PMID: 8625302.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnimalsBiomarkers, TumorBrain NeoplasmsBrevicanCarrier ProteinsChild, PreschoolChondroitin Sulfate ProteoglycansFemaleGliomaHumansHyaluronic AcidIn Situ HybridizationLectins, C-TypeMaleMiddle AgedNeoplasm InvasivenessNeoplasm ProteinsNeoplasm TransplantationNerve Tissue ProteinsRatsRats, Inbred LewRats, Sprague-DawleyTumor Cells, CulturedConceptsGlioma cell linesSurgical samplesIntracranial graftsCell linesAdult human cortexInvasive glioma cell linesBrain metastasesNonglial tumorsNoninvasive cell linesMalignant gliomasExtracellular brainNormal brainTumor invasionHyaluronan-binding proteinHuman cortexGliomasTumorsInvasive behaviorStandard cell culture conditionsGraftBrainBEHABCell culture conditionsSelective markerMetastasisA phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain
Halperin E, Herndon J, Schold S, Brown M, Vick N, Cairncross J, Macdonald D, Gaspar L, Fischer B, Dropcho E, Rosenfeld S, Morowitz R, Piepmeier J, Hait W, Byrne T, Salter M, Imperato J, Khandekar J, Paleologos N, Burger P, Bentel G, Friedman A. A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. International Journal Of Radiation Oncology • Biology • Physics 1996, 34: 793-802. PMID: 8598355, DOI: 10.1016/0360-3016(95)02025-x.Peer-Reviewed Original ResearchConceptsExternal beam radiotherapyKarnofsky performance statusMedian survivalSurvival benefitERT groupAnaplastic gliomasBeam radiotherapyMitomycin CVs. 11.4 monthsProportion of patientsSignificant survival benefitPossible survival benefitTreatment of adultsYears of ageBCNU groupPerformance statusProspective trialHistologic diagnosisMalignant gliomasMito groupStereotactic biopsyPatientsGreater riskFourth weekThird day
1993
Low-grade astrocytomas may arise from different astrocyte lineages.
Piepmeier J, Fried I, Makuch R. Low-grade astrocytomas may arise from different astrocyte lineages. Neurosurgery 1993, 33: 627-32. PMID: 8232801, DOI: 10.1227/00006123-199310000-00010.Peer-Reviewed Original ResearchConceptsLow-grade astrocytomasGlial fibrillary acidic protein-positive cellsFibrillary acidic proteinProtein-positive cellsAstrocyte lineagePreoperative symptomsAnti-glial fibrillary acidic proteinAcidic proteinGlial fibrillary acidic proteinLong preoperative historyCommon histological featuresDifferent clinical manifestationsPercentage of cellsPreoperative historyClinical manifestationsHistological featuresImaging featuresRate of proliferationImmunohistochemical analysisAstrocytic phenotypeNeoplastic cellsType 2White matterAstrocytomasTumors
1990
The effect of calmodulin inhibitors with bleomycin on the treatment of patients with high grade gliomas.
Hait W, Byrne T, Piepmeier J, Durivage H, Choudhury S, Davis C, Gates J. The effect of calmodulin inhibitors with bleomycin on the treatment of patients with high grade gliomas. Cancer Research 1990, 50: 6636-40. PMID: 1698540.Peer-Reviewed Original ResearchConceptsCentral nervous systemClinical trialsNormal brainNervous systemPhase II clinical trialPhase I clinical trialFatal pulmonary toxicityObjective tumor responseTreatment of patientsHigh-grade gliomasComplete responseCombination therapyPulmonary toxicityTumor responseFatal malignancyMalignant gliomasPreclinical modelsPharmacological characteristicsGrade gliomasGlioblastoma multiformePatientsGliomasRat cerebrumCalmodulin inhibitorsBleomycinA Randomized, Controlled Trial of Methylprednisolone or Naloxone in the Treatment of Acute Spinal-Cord Injury
Bracken M, Shepard M, Collins W, Holford T, Young W, Baskin D, Eisenberg H, Flamm E, Leo-Summers L, Maroon J, Marshall L, Perot P, Piepmeier J, Sonntag V, Wagner F, Wilberger J, Winn H. A Randomized, Controlled Trial of Methylprednisolone or Naloxone in the Treatment of Acute Spinal-Cord Injury. New England Journal Of Medicine 1990, 322: 1405-1411. PMID: 2278545, DOI: 10.1056/nejm199005173222001.Peer-Reviewed Original ResearchConceptsAcute spinal cord injurySpinal cord injuryNeurologic recoverySafety of methylprednisoloneSystematic neurological examinationPlacebo-controlled trialHours of injuryMajor morbidityNeurologic outcomeControlled TrialsNeurological examinationIncomplete lesionsMotor functionMethylprednisoloneNaloxonePatientsBody weightSensory functionInjuryPlaceboInfusionBolusEffective remainsTreatmentDose
1988
Late neurological changes following traumatic spinal cord injury.
Piepmeier J, Jenkins N. Late neurological changes following traumatic spinal cord injury. Journal Of Neurosurgery 1988, 69: 399-402. PMID: 3404238, DOI: 10.3171/jns.1988.69.3.0399.Peer-Reviewed Original ResearchConceptsSpinal cord injuryTraumatic spinal cord injuryCord injuryNeurological functionPatient's spinal cord injuryFunctional neurological statusFrankel scaleNeurological statusNeurological examinationSpinal traumaYears postinjuryNeurological changesPatient statusInjuryMajority of improvementsPatientsExaminationSignificant changesStatusYearsPostinjuryHospitalTraumaPrimary leptomeningeal sarcomatosis. Case report.
Thibodeau L, Ariza A, Piepmeier J. Primary leptomeningeal sarcomatosis. Case report. Journal Of Neurosurgery 1988, 68: 802-5. PMID: 3357038, DOI: 10.3171/jns.1988.68.5.0802.Peer-Reviewed Original ResearchConceptsCerebrospinal fluid examinationMultiple cranial nervesPrimary leptomeningeal sarcomatosisMeningeal diseaseFluid examinationSurgical explorationClinical evidenceOpen biopsyCase reportPathological diagnosisProgressive deficitsCranial nervesSpinal rootsInvasive methodBiopsyDiffuse processDiseaseDiagnosisReportSarcomatosisLeptomeningesPatientsNerve
1987
Observations on the current treatment of low-grade astrocytic tumors of the cerebral hemispheres.
Piepmeier J. Observations on the current treatment of low-grade astrocytic tumors of the cerebral hemispheres. Journal Of Neurosurgery 1987, 67: 177-81. PMID: 3598677, DOI: 10.3171/jns.1987.67.2.0177.Peer-Reviewed Original ResearchConceptsLow-grade astrocytic tumorsComputerized tomographyCerebral hemispheresAstrocytic tumorsPreoperative neurological examinationUse of CTCurrent treatment methodsTreatment methodsPatient ageNeurological examinationTotal resectionTumor locationCurrent treatmentIntravenous administrationCT scanEarly diagnosisSurvival timeTumor enhancementContrast materialOptimal managementOnly factorPatientsLesionsOutcome statisticsTumorsCardiovascular abnormalities accompanying acute spinal cord injury in humans: Incidence, time course and severity
Lehmann K, Lane J, Piepmeier J, Batsford W. Cardiovascular abnormalities accompanying acute spinal cord injury in humans: Incidence, time course and severity. Journal Of The American College Of Cardiology 1987, 10: 46-52. PMID: 3597994, DOI: 10.1016/s0735-1097(87)80158-4.Peer-Reviewed Original ResearchConceptsCord injurySpinal cordCardiovascular abnormalitiesAcute spinal cord injuryAcute severe injuryCervical cord injuryPrimary cardiac arrestCervical spinal cordSpinal cord injuryLife-threatening disturbancesMild cervical injuriesPersistent bradycardiaAutonomic imbalanceCervical cordHemodynamic abnormalitiesInjury groupSympathetic pathwaysConsecutive patientsCord traumaCervical injuryAcute injurySupraventricular arrhythmiasCardiac arrestSevere injuriesDay 4
1985
A phase I trial of naloxone treatment in acute spinal cord injury.
Flamm E, Young W, Collins W, Piepmeier J, Clifton G, Fischer B. A phase I trial of naloxone treatment in acute spinal cord injury. Journal Of Neurosurgery 1985, 63: 390-7. PMID: 3894597, DOI: 10.3171/jns.1985.63.3.0390.Peer-Reviewed Original ResearchConceptsGroup 2 patientsSpinal cord injuryAcute spinal cord injuryPhase I trialTime of admissionLoading doseCord injuryMaintenance doseI trialExperimental spinal cord injuryComplete neurological deficitGroup 1 patientsWeeks of admissionDose-related fashionTreatment of patientsOpiate antagonist naloxoneIncomplete deficitsMaintenance infusionNeurological deficitsNeurological statusNaloxone treatmentNeurological examinationAntagonist naloxoneInitial doseContinuous infusion